WHO sets development targets for long-acting TB injectables
The World Health Organization has published target regimen profiles for long-acting injectables in tuberculosis prevention and treatment, drawing a line between what would be merely interesting and what would be clinically usable. The document arrives at a moment when TB care still leans heavily on daily oral therapy taken over months, a structure that is difficult to sustain for many patients and burdensome for the health systems that must deliver it.
Long-acting formulations have already altered care in other fields, most visibly HIV. For TB, the promise is simpler dosing, fewer adherence failures, and less treatment fatigue — but only if the regimen preserves efficacy, safety, and patient choice. A shorter route into care can still fail if the product is too complex to give, too expensive to scale, or too inflexible for the people who need it.
The profiles are designed to guide product development early, before programs and companies commit to designs that cannot realistically be deployed. They set out both minimal and optimal requirements for new regimens, giving developers a practical framework for preventive treatment and for active disease. In effect, WHO is telling the field what a workable TB injectable must accomplish long before it reaches clinical use.
Preventive treatment aims for a single-visit injection course
The profile for TB preventive treatment is intentionally ambitious. It calls for a full course delivered as a single injection at one encounter, which would remove the need for repeated daily dosing over weeks or months. For prevention, the appeal is obvious: a one-time intervention is less vulnerable to missed doses, lost follow-up, and the social barriers that often interrupt oral therapy in real-world settings.
The clinical logic is straightforward. TB preventive treatment succeeds when enough drug exposure is maintained long enough to suppress progression from latent infection to disease, but oral regimens depend on daily behavior over long periods. An injectable platform shifts that burden from the patient to the formulation itself, creating the possibility of steadier pharmacokinetics and more reliable coverage if the product can maintain effective levels for the required duration.
The profile also specifies how such a regimen should be delivered. Injections should be given by a trained health worker at the lowest feasible level of the health system, with small injection volumes and no cold chain requirement. Those details matter because they determine whether the product can move beyond specialized centers and into routine TB services, community clinics, and decentralized care pathways.
TB disease treatment must stay short, practical, and comparable to oral therapy
For active TB disease, WHO defines a regimen of no more than four months, delivered in three or fewer dosing encounters. The goal is not simply to replace pills with needles. The goal is to compress treatment burden without weakening the standard of care.
Both profiles require efficacy and safety at least as good as current oral regimens. That condition is central. A long-acting product that reduces visit frequency but sacrifices microbiologic control would create a false economy, especially in a disease where incomplete treatment can prolong illness, sustain transmission, and foster resistance. A durable formulation only helps if it can clear or suppress infection with the same confidence clinicians expect from established therapy.
The document also addresses broader implementation issues that often determine whether a promising product survives in the field. Trial design, overall treatment burden, scalability, equitable access, transparent pricing, and cost are all included. Those topics are not peripheral in TB; they are part of the therapeutic equation. A regimen that is biologically sound but operationally inaccessible will not alter outcomes at population level.
Development guidance extends beyond pharmacology
WHO convened a Scientific TRP Development Group to build the profiles, bringing together trialists, pharmacologists, regulators, national TB programme officers, people with lived experience of TB, and civil society representatives. That mix reflects the reality that TB innovation fails when it is shaped only by laboratory feasibility or commercial enthusiasm. Delivery constraints, acceptability, and patient preference determine whether a regimen is adopted, tolerated, and sustained.
The group’s work was informed by a landscape analysis, a public consultation held in April and May 2026, and additional community and provider surveys, focus group discussions, and a multicountry discrete choice experiment. Those inputs suggest a deliberate effort to match product design with real-world preferences rather than assume that fewer doses automatically equals better care.
The inclusion of trade-offs in the profiles is especially important. Long-acting injectables can reduce dosing frequency, but they may introduce other constraints, including injection burden, formulation complexity, or access inequities if delivery infrastructure is too narrow. A regimen profile that spells out trade-offs early can steer development toward products that are not only pharmacologically durable but also serviceable in health systems with limited resources.
Oral options still matter for patient choice
WHO also makes clear that better oral regimens should continue to advance in parallel. Some people will prefer not to receive injections, and implementation should preserve that choice. TB treatment will not be improved by replacing one rigid model with another. A durable injectable should expand options, not eliminate them.
That point matters in practice because TB programs serve patients with very different needs, preferences, and degrees of access to care. One patient may value the simplicity of a single injection; another may prefer pills because of needle aversion, clinic distance, or prior experience with injections. Keeping both routes in play allows programs to match treatment to the person rather than force a single formulation onto every setting.
The publication now gives developers a clear benchmark for what a long-acting TB regimen must achieve to justify further investment. The next barrier is not conceptual. It is whether candidate products can meet those efficacy, safety, delivery, and access requirements in trials that are rigorous enough to support real-world use.